Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo

Journal of Medicinal Chemistry

Volumn 47, Issue 24, 2004, Pages 5825-5828

  Lindsley, Craig W ^a   Wisnoski, David D ^a   Leister, William H ^a   O'Brien, Julie A ^a   Lemaire, Wei ^a   Williams Jr , David L ^a   Burno, Maryann ^a   Sur, Cyrille ^a   Kinney, Gene G ^a   Pettibone, Doug J ^a   Tiller, Philip R ^a   Smith, Sheri ^a   Duggan, Mark E ^a   Hartman, George D ^a   Conn, P Jeffrey ^a   Huff, Joel R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 CYANO N (1,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; BENZAMIDE DERIVATIVE; GLUTAMIC ACID; METABOTROPIC RECEPTOR 5; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; IN VIVO STUDY; NONHUMAN; PREPULSE INHIBITION; RAT; SCHIZOPHRENIA;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BRAIN; CHO CELLS; CRICETINAE; CRICETULUS; GLUTAMIC ACID; HUMANS; PYRAZOLES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STARTLE REACTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 8644252687     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049400d     Document Type: Article

References (25)

1. Schoepp, D. D.; Jane, D. E.; Monn, J. A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38, 1431-1476.
2. Conn, P. J.; Pin, J.-P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237.
3. Alagarsamy, S.; Sorensen, S. D.; Conn, P. J. Coordinate regulation of metabotropic glutamate receptors. Curr. Opin. Neurobiol. 2001, 3, 114-120.
4. Chavez-Noriega, L. E.; Schaffhauser, H. J-L., Campbell, U. C. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 2002, 1, 261-281.
5. (a) Olney, J. W.; Farber, N. B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 1995, 52, 998-1007.
6. (b) Olney, J. W.; Newcomer, J. W.; Farber, N. B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 1999, 33, 523-533.
7. Mannaioni, G.; Marino, M. J.; Valenti, O.; Traynelis, S. F.; Conn, P. J. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyrimidal cell function. J. Neurosci. 2001, 21, 5925-5934.
8. Cartmell, J.; Schoepp, D. D. Regulation of neurotransmitter release by metabotropic glutamate receptor. J. Neurochem. 2000, 75, 889-907.
9. Gasparini, F.; Kuhn, R.; Pin, J.-P. Allosteric modulators of group I metabotropic glutamate receptors: novelsubtype-selective ligands and therapeutic perspectives. Curr. Opin. Pharmacol. 2002, 2, 43-49.
10. (a) Lischig, S.; Gasparini, F.; Ruegg, D.; Stoehr, N.; Flor, P. J.; Vranesic, I.; Prezeau, L.; Pin, J.-P.; Thomsen, C.; Kuhn, R. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. 1999, 55, 453-461.
11. (b) Gasparini, F.; Lingenhohl, K.; Stoehr, N. Flor, P. J.; Heinrich, M.; Vranesic, I., et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGluR5 receptor antagonist. Neuropharmacology 1999, 38, 1493-1503.
12. (a) Knoflach, F.; Mutel, V.; Jolidon, S.; Kew, J. N. C.; Malherbe, P.; Vieira, E.; Wichmann, J.; Kemp, J. A. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action and binding site. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 13402-13407.
13. (b) Johnson, M. P.; Baez, M.; Jagdmann, G. E.; Britton, T. C.; Large, T. H.; Callagaro, D. O.; Tizzano, J. P.; Monn, J. A.; Schoepp, D. D. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J. Med. Chem. 2003, 46, 3189-3192.
14. (a) O'Brien, J. A.; Lemaire, W.; Chen, T.-B.; Chang, R. S. L.; Jacobson, M. A.; Ha, S. N.; Lindsley, C. W.; Sur, C.; Pettibone, D. J.; Conn, J.; Wiliams, D. L. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). Mol. Pharmacol. 2003, 64 (3), 731.
15. (b) O'Brien, J. A.; Lemaire, W.; Wittman, M.; Jacobson, M. A.; Ha, S. N.; Wisnoski, D. D.; Lindsley, C. W.; Schaffhauser, H. J.; Sur, C.; Duggan, M. E.; Pettibone, D. J.; Conn, P. J.; Wiliams, D. L. 'A novel, selective allosteric modulator potentitaes the activity of native metabotropic glutamate receptor subtype 5 (mGluR5) in rat forebrain. J. Pharmacol. Exp. Ther. 2004, 309 (2), 568-577.
16. Unfortunately, we did not have access to an mGluR6 cell line, so we could not evaluate selectivity vs mGluR5 in this instance.
17. Leister, W.; Strauss, K.; Wisnoski, D..; Zhao, Z.; Lindsley, C. Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries. J. Comb. Chem. 2003, 5, 322.
18. Kinney, G. G.; O'Brien, J. A.; Lemaire, W.; Burno, M.; Bickel, D. J.; Clements, M. K.; Wisnoski, D. W.; Lindsley, C. W.; Tiller, P. R.; Smith, S.; Jacobson, M. A.; Sur, S.; Duggan, M. E.; Pettibone, D. J.; Williams, D. L., Jr. A novel selective allosteric modulator of Metabotropic glutamate receptor subtype 5 (mGluR5) has an antipsychotic profile in rats behavioral models. J. Neurosci., submitted.
19. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madweed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate. J. Med. Chem. 2002, 45, 2994-3008.
20. 50 of 9.7 μM.
21. Hochman, J. H.; Yamazaki, M.; Ohe, T.; Lin, J. H. Evaluation of drug interactions with P-glycoprotein: in vitro assessment of the potential for drug-drug intreractions with P-glycoprotein. Curr. Drug Methods 2002, 3, 257-273 and references therein.
22. Kinney, G. G.; Burno, M.; Campbell, U. C.; Hernandez, L. M.; Rodriguez, D.; Bristow, L. J.; Conn, J. P. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 2003, 306, 116-123.
23. Geyer, M. A.; Krebs-Thomoson, K.; Braff, D. L.; Swerdlow, N. R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001, 156, 117-154.
24. (a) Bristow, L. J.; Thorn, L.; Tricklebank, M. D.; Huston, P. H. Competitive NMDA receptor antagonists attenuate the behavioral and neurochemical effects of amphetamine in mice. Eur. J. Pharmacol. 1994, 264, 353-359.
25. (b) Kumari, V.; Sharma, T. Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology 2002, 162, 97-101.